Weekly Investment Analysts’ Ratings Updates for BeOne Medicines (ONC)
by Doug Wharley · The Cerbat GemSeveral brokerages have updated their recommendations and price targets on shares of BeOne Medicines (NASDAQ: ONC) in the last few weeks:
- 8/10/2026 – BeOne Medicines had its “outperform” rating reaffirmed by Wolfe Research. They now have a $370.00 price target on the stock.
- 8/7/2026 – BeOne Medicines was upgraded by Zacks Research from “hold” to “strong-buy”.
- 8/6/2026 – BeOne Medicines had its “overweight” rating reaffirmed by Morgan Stanley.
- 8/6/2026 – BeOne Medicines had its “outperform” rating reaffirmed by Citigroup Inc..
- 8/6/2026 – BeOne Medicines had its price target raised by Barclays PLC from $403.00 to $407.00. They now have an “overweight” rating on the stock.
- 8/6/2026 – BeOne Medicines had its price target raised by TD Cowen from $424.00 to $454.00. They now have a “buy” rating on the stock.
- 8/6/2026 – BeOne Medicines had its price target lowered by Royal Bank Of Canada from $451.00 to $450.00. They now have an “outperform” rating on the stock.
- 8/6/2026 – BeOne Medicines had its price target raised by Truist Financial Corporation from $416.00 to $418.00. They now have a “buy” rating on the stock.
- 8/6/2026 – BeOne Medicines had its price target raised by Guggenheim from $420.00 to $430.00. They now have a “buy” rating on the stock.
- 8/6/2026 – BeOne Medicines had its price target raised by Citizens Jmp from $396.00 to $405.00. They now have a “market outperform” rating on the stock.
- 7/27/2026 – BeOne Medicines was upgraded by Nomura to “strong-buy”.
- 7/23/2026 – BeOne Medicines had its price target raised by JPMorgan Chase & Co. from $415.00 to $425.00. They now have an “overweight” rating on the stock.
- 7/18/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 7/17/2026 – BeOne Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/14/2026 – BeOne Medicines had its price target lowered by Barclays PLC from $409.00 to $403.00. They now have an “overweight” rating on the stock.
- 7/7/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $436.00 to $451.00. They now have an “outperform” rating on the stock.
- 7/7/2026 – BeOne Medicines had its price target raised by Truist Financial Corporation from $413.00 to $416.00. They now have a “buy” rating on the stock.
- 7/6/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 7/3/2026 – BeOne Medicines was downgraded by Zacks Research from “strong-buy” to “hold”.
- 7/1/2026 – BeOne Medicines had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $396.00 price target on the stock.
- 6/28/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 6/20/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
Insider Transactions at BeOne Medicines
In other news, CEO John Oyler sold 145,861 shares of BeOne Medicines stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the transaction, the chief executive officer directly owned 8,122 shares in the company, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 586,039 shares of company stock worth $192,002,587. Company insiders own 6.19% of the company’s stock.
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.